ProfileGDS5678 / 1427934_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 80% 74% 75% 78% 79% 72% 72% 75% 75% 76% 75% 79% 74% 75% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 15.5605280
GSM967853U87-EV human glioblastoma xenograft - Control 24.8535474
GSM967854U87-EV human glioblastoma xenograft - Control 34.994675
GSM967855U87-EV human glioblastoma xenograft - Control 45.4791378
GSM967856U87-EV human glioblastoma xenograft - Control 55.5809279
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 14.5568672
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 24.5590872
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 34.935775
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 44.9351675
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 15.1727476
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 24.9264675
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 35.6157279
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 44.8722274
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 54.9566375